Literature DB >> 3774121

5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis.

B Costall, A M Domeney, R J Naylor, F D Tattersall.   

Abstract

The administration to the ferret of cisplatin, 10mg/kg (i.v.), caused an intense emetic response that was prevented by ICS 205-930 (0.1 and 1.0 mg/kg i.v.) and metoclopramide (4.0 mg/kg i.v.). Smaller doses of ICS 205-930 (0.01 mg/kg i.v.) and metoclopramide (2.0 mg/kg i.v.) attenuated the emetic response to cisplatin. It is concluded that the potent action of ICS 205-930 against cisplatin-induced emesis is the consequence of a 5-hydroxytryptamine M-receptor antagonism which may also contribute to the antiemetic action of metoclopramide.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3774121     DOI: 10.1016/0028-3908(86)90030-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  46 in total

1.  Characterization of the 5-hydroxytryptamine receptors mediating contraction in the intestine of Suncus murinus.

Authors:  F A Javid; R J Naylor
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 2.  Neuropharmacology of emesis in relation to clinical response.

Authors:  B Costall; R J Naylor
Journal:  Br J Cancer Suppl       Date:  1992-12

3.  Proceedings of the British Pharmacological Society. 12-14 September 1990, Belfast.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

4.  The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties.

Authors:  J R Stott; G R Barnes; R J Wright; C J Ruddock
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

5.  Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.

Authors:  A Hamik; S J Peroutka
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy.

Authors:  D B Smith; E S Newlands; G J Rustin; R H Begent; S M Crawford; K D Bagshawe; L Carruthers
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  5-Hydroxytryptamine is emetogenic in the house musk shrew, Suncus murinus.

Authors:  Y Torii; H Saito; N Matsuki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

Review 8.  5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.

Authors:  M S Aapro
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

9.  Effects of a 5-hydroxytryptamine3 receptor antagonist (ICS 205-930) on colonic motor activity in healthy men.

Authors:  G Stacher; G Gaupmann; C Schneider; G Stacher-Janotta; G Steiner-Mittelbach; T A Abatzi; H Steinringer
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

10.  Hypothermia induced by m-trifluoromethylphenylpiperazine or m-chlorophenylpiperazine: an effect mediated by 5-HT1B receptors?

Authors:  J Maj; E Chojnacka-Wójcik; A Kłodzińska; A Dereń; E Moryl
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.